171 related articles for article (PubMed ID: 38019269)
21. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China.
Xing P; Li J; Jin F
Med Oncol; 2010 Sep; 27(3):926-31. PubMed ID: 19771534
[TBL] [Abstract][Full Text] [Related]
22. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.
Phipps AI; Buist DS; Malone KE; Barlow WE; Porter PL; Kerlikowske K; Li CI
Breast Cancer Res Treat; 2011 Apr; 126(3):671-8. PubMed ID: 20814817
[TBL] [Abstract][Full Text] [Related]
23. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
24. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer molecular subtypes and receptor status among women at Potchefstroom Hospital: a cross-sectional study.
Kakudji BK; Mwila PK; Burger JR; du Plessis JM; Naidu K
Pan Afr Med J; 2021; 38():85. PubMed ID: 33889251
[TBL] [Abstract][Full Text] [Related]
26. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
Breast J; 2022; 2022():9238804. PubMed ID: 35711896
[TBL] [Abstract][Full Text] [Related]
27. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
28. The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score.
Yang ZJ; Liu YX; Huang Y; Chen ZJ; Zhang HZ; Yu Y; Wang X; Cao XC
Cancer Med; 2023 Feb; 12(3):2493-2504. PubMed ID: 35909232
[TBL] [Abstract][Full Text] [Related]
29. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
Parise C; Caggiano V
Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
[TBL] [Abstract][Full Text] [Related]
30. Association between mammographic density and tumor marker-defined breast cancer subtypes: a case-control study.
Shin J; Lee JE; Ko HY; Nguyen TL; Nam SJ; Hopper JL; Song YM
Eur J Cancer Prev; 2018 May; 27(3):239-247. PubMed ID: 28957821
[TBL] [Abstract][Full Text] [Related]
31. Association between common risk factors and molecular subtypes in breast cancer patients.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
[TBL] [Abstract][Full Text] [Related]
32. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study.
Ma H; Wang Y; Sullivan-Halley J; Weiss L; Marchbanks PA; Spirtas R; Ursin G; Burkman RT; Simon MS; Malone KE; Strom BL; McDonald JA; Press MF; Bernstein L
Cancer Res; 2010 Jan; 70(2):575-87. PubMed ID: 20068186
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer recurrence according to molecular subtype.
Shim HJ; Kim SH; Kang BJ; Choi BG; Kim HS; Cha ES; Song BJ
Asian Pac J Cancer Prev; 2014; 15(14):5539-44. PubMed ID: 25081661
[TBL] [Abstract][Full Text] [Related]
34. [Long-term survival analysis of different breast cancer molecular subtypes: Shanghai Breast Cancer Survival Study].
Bao P; Peng P; Gu K; Wu C; Huang Z; Gong Y; Zhang M; Zheng Y
Zhonghua Wai Ke Za Zhi; 2015 Dec; 53(12):928-34. PubMed ID: 26850665
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
36. The impact of selected risk factors among breast cancer molecular subtypes: a case-only study.
Pizzato M; Carioli G; Rosso S; Zanetti R; La Vecchia C
Breast Cancer Res Treat; 2020 Nov; 184(1):213-220. PubMed ID: 32851454
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
Lin NU; Vanderplas A; Hughes ME; Theriault RL; Edge SB; Wong YN; Blayney DW; Niland JC; Winer EP; Weeks JC
Cancer; 2012 Nov; 118(22):5463-72. PubMed ID: 22544643
[TBL] [Abstract][Full Text] [Related]
38. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups.
Kurian AW; Fish K; Shema SJ; Clarke CA
Breast Cancer Res; 2010; 12(6):R99. PubMed ID: 21092082
[TBL] [Abstract][Full Text] [Related]
39. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.
Carvalho FM; Bacchi LM; Pincerato KM; Van de Rijn M; Bacchi CE
BMC Womens Health; 2014 Aug; 14():102. PubMed ID: 25174527
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study.
Kim EK; Noh WC; Han W; Noh DY
World J Surg; 2011 Jun; 35(6):1244-53. PubMed ID: 21472372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
